Mannose Receptor High, M2 Dermal Macrophages Mediate Nonhealing Infection in a Th1 Immune Environment
Overview
General Medicine
Authors
Affiliations
The origin and functional specialization of dermal macrophages in cutaneous infections have been little studied. In this paper, we show that a strain of ( Seidman [LmSd]) that produces nonhealing cutaneous lesions in conventionally resistant C57BL/6 mice was more efficiently taken up by M2-polarized bone marrow (BM)-derived macrophages (BMDMs) in vitro and by mannose receptor (MR) dermal macrophages in vivo compared with a healing strain ( Friedlin V1). Both in steady and in T helper type 1 (Th1) cell-driven inflammatory states, the MR dermal macrophages showed M2 characteristics. The dermal macrophages were radio resistant and not replaced by monocytes or adult BM-derived cells during infection, but were locally maintained by IL-4 and IL-10. Notably, the favored infection of M2 BMDMs by LmSd in vitro was MR dependent, and genetic deletion of MR or selective depletion of MR dermal macrophages by anti-CSF-1 receptor antibody reversed the nonhealing phenotype. We conclude that embryonic-derived, MR dermal macrophages are permissive for parasite growth even in a strong Th1-immune environment, and the preferential infection of these cells plays a crucial role in the severity of cutaneous disease.
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.
Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.
PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.
Restrepo C, Llanes A, Herrera L, Ellis E, Quintero I, Fernandez P Exp Biol Med (Maywood). 2025; 249():10377.
PMID: 39830895 PMC: 11740880. DOI: 10.3389/ebm.2024.10377.
Tissue-resident immune cells: from defining characteristics to roles in diseases.
Li J, Xiao C, Li C, He J Signal Transduct Target Ther. 2025; 10(1):12.
PMID: 39820040 PMC: 11755756. DOI: 10.1038/s41392-024-02050-5.
Resilience of dermis resident macrophages to inflammatory challenges.
Lee S, Sacks D Exp Mol Med. 2024; 56(10):2105-2112.
PMID: 39349826 PMC: 11542019. DOI: 10.1038/s12276-024-01313-z.
Silva J, Silva H, Sarmento A, Hueb M, Damazo A Rev Soc Bras Med Trop. 2024; 57:e00412.
PMID: 39082522 PMC: 11290842. DOI: 10.1590/0037-8682-0036-2024.